Apollo Care, LLC: GLP-1 NDC Listings (Oct 2026)

What FDA’s records state

FDA listing summary for Apollo Care, LLC
Field	What FDA’s record states	Source
Firm, as FDA lists it	Apollo Care, LLC	FDA compounded file
Also listed as	No other spelling	FDA compounded file
FDA labeler code	71170	FDA compounded file
Molecules	Semaglutide, Tirzepatide	FDA compounded file
Kinds of listing	503B compounded: 8	FDA compounded file
Products and packages	8 products, 8 package NDCs	FDA compounded file
Earliest listing date	Not published by FDA	n/a
Latest listing date	Not published by FDA	n/a
503B product reports	second-half 2024 report, second-half 2025 report, first-half 2026 report	FDA compounded file

Every GLP-1 product Apollo Care, LLC lists

One row per product NDC, in FDA’s words. Strength is printed as FDA lists it, spacing tidied.

GLP-1 products listed with FDA by Apollo Care, LLC
Product	Product NDC	Form and strength	FDA category	Listed	Packages
Semaglutide 12.5 mgSemaglutide	71170-495	Injection, Solution · Subcutaneous2.5 mg/mL	503B compoundedOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)	second-half 2025 report, first-half 2026 report	1 package 71170-495-05 5 mL in 1 VIAL, MULTI-DOSE
Semaglutide 12.5mg and Cyanocobalamin 2.5mgSemaglutide	71170-690	Injection, Solution · SubcutaneousSemaglutide 2.5 mg/mL; Cyanocobalamin 0.5 mg/mL	503B compoundedOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)	second-half 2024 report	1 package 71170-690-01 5 mL in 1 VIAL, MULTI-DOSE
Semaglutide 1mg and Cyanocobalamin 0.5mgSemaglutide	71170-640	Injection, Solution · SubcutaneousSemaglutide 1 mg/mL; Cyanocobalamin 0.5 mg/mL	503B compoundedOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)	second-half 2024 report	1 package 71170-640-01 1 mL in 1 VIAL, MULTI-DOSE
Semaglutide 2.25 mgSemaglutide	71170-811	Injection, Solution · Subcutaneous0.9 mg/mL	503B compoundedOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)	second-half 2025 report, first-half 2026 report	1 package 71170-811-02 2.5 mL in 1 VIAL, MULTI-DOSE
Semaglutide 2.5mg and Cyanocobalamin 0.5mgSemaglutide	71170-650	Injection, Solution · SubcutaneousSemaglutide 2.5 mg/mL; Cyanocobalamin 0.5 mg/mL	503B compoundedOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)	second-half 2024 report	1 package 71170-650-01 1 mL in 1 VIAL, MULTI-DOSE
Semaglutide 6.75 mgSemaglutide	71170-821	Injection, Solution · Subcutaneous4.5 mg/mL	503B compoundedOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)	second-half 2025 report, first-half 2026 report	1 package 71170-821-01 1.5 mL in 1 VIAL, MULTI-DOSE
Tirzepatide 20mg and Pyridoxine 8mgTirzepatide	71170-610	Injection, Solution · SubcutaneousTirzepatide 10 mg/mL; Pyridoxine Hydrochloride 4 mg/mL	503B compoundedOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)	second-half 2024 report	1 package 71170-610-01 2 mL in 1 VIAL, MULTI-DOSE
Tirzepatide 60mg and Pyridoxine 12mgTirzepatide	71170-630	Injection, Solution · SubcutaneousTirzepatide 20 mg/mL; Pyridoxine Hydrochloride 4 mg/mL	503B compoundedOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)	second-half 2024 report	1 package 71170-630-01 3 mL in 1 VIAL, MULTI-DOSE

The rest of its federal record

Checked against every GLP-1 record we publish from FDA. A recall or shortage counts when FDA printed one of this firm’s NDCs in it; a letter or 503B entry counts when the firm name matches exactly. Similar names are listed apart and not counted.

503B outsourcing facility register

GLP-1 warning letters

None of the GLP-1 warning letters we hold is addressed to this name.

GLP-1 recalls

Class II, ongoing, reported Aug 19, 2026: Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialD-0747-2026 · Apollo Care, LLC · matched by NDC
Class II, ongoing, reported Aug 19, 2026: Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialD-0748-2026 · Apollo Care, LLC · matched by NDC
Class II, ongoing, reported Aug 19, 2026: Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialD-0749-2026 · Apollo Care, LLC · matched by NDC
Class II, ongoing, reported Aug 19, 2026: Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialD-0750-2026 · Apollo Care, LLC · matched by name
Class II, ongoing, reported Aug 19, 2026: Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialD-0751-2026 · Apollo Care, LLC · matched by name
Class II, ongoing, reported Aug 19, 2026: Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialD-0752-2026 · Apollo Care, LLC · matched by name
Class II, ongoing, reported Aug 19, 2026: Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialD-0753-2026 · Apollo Care, LLC · matched by name
Class II, ongoing, reported Aug 19, 2026: Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialD-0754-2026 · Apollo Care, LLC · matched by name
Class II, ongoing, reported Aug 19, 2026: Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialD-0755-2026 · Apollo Care, LLC · matched by name
Class II, ongoing, reported Aug 19, 2026: Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialD-0756-2026 · Apollo Care, LLC · matched by name
Class II, ongoing, reported Aug 19, 2026: Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialD-0757-2026 · Apollo Care, LLC · matched by name

FDA enforcement reports, updated by FDA Sep 23, 2026. Every GLP-1 recall

FDA drug shortage list

None of this firm’s NDCs is on FDA’s GLP-1 shortage entries.

FDA drug shortages ↗, updated by FDA Oct 2, 2026.

What these listings mean, and what they do not

503B compounded. A drug a 503B outsourcing facility compounded and reported to FDA. FDA's own category name for these is "exempt from approval requirements": nobody has approved the product.

A listing is not an approval, and not a quality check. It tells FDA a firm makes, labels or compounds a drug. Whether a product was approved is a question about its application, shown above where there is one. Whether a plant passed inspection is a different record again.

The molecules. Semaglutide is the ingredient in Ozempic, Wegovy, Rybelsus; Tirzepatide is the ingredient in Mounjaro, Zepbound.

“Inclusion in the NDC Directory does not indicate that FDA has verified the information provided or that the products are FDA-approved.”FDA, National Drug Code Directory page, confirmed on the page Oct 4, 2026. fda.gov ↗

“Assignment of an NDC number does not in any way denote FDA approval of the product.”FDA, National Drug Code Directory page, confirmed on the page Oct 4, 2026. fda.gov ↗

“The content of each NDC Directory entry is the responsibility of the labeler submitting the SPL file.”FDA, National Drug Code Directory page, confirmed on the page Oct 4, 2026. fda.gov ↗

“Outsourcing facilities that have elected to assign NDCs to their products provide FDA with a list of drugs they compounded during the previous six-month period upon initial registration and in June and December each year.”FDA, National Drug Code Directory page, confirmed on the page Oct 4, 2026. fda.gov ↗

Related records

Other firms listing semaglutide and tirzepatide

FDA registers on this site

Sources

FDA’s compounded drugs file ↗, last replaced by FDA Sep 18, 2026.
FDA’s National Drug Code Directory page ↗ for the quoted definitions.
Read by us Oct 4, 2026. Not medical advice; this page describes filings, not products’ safety.